Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.8%

Neg 0% Neu 90.8% Pos 0%

Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.

Comments

No comments yet. Be the first!